Compare Twist Bioscience Corp (TWST) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wix.Com Ltd — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Wix.Com Ltd trades at $53.52 (market cap $2.23B). The key difference: Twist Bioscience Corp is far larger — about 2.4× Wix.Com Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| TWST | WIX | |
|---|---|---|
Market Cap | $5.45B | $2.23B |
Sector | Health | Technology |
52-Week High | $102.88 | $184.24 |
52-Week Low | $24.16 | $40.43 |
Enterprise Value | $5.37B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Wix.com trades at $51.12, down 0.64% on the day, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. Revenue growth remains strong, reaching $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news includes product launches like Wix Headless AI integration and multiple law firm investigations into potential securities fraud following a 56% stock decline in H1 2026.
The stock presents a high-risk, high-reward profile with a consensus price target of $77.50 implying 52% upside, but faces headwinds from earnings volatility, negative equity, and legal scrutiny. Long-term growth drivers in AI and small business tools are countered by near-term execution risks and competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
